drugset / Trial / NCT01030718
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Parallel-groupOpen-labelTreatment
Summary
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant or intolerant to treatment and will continue study drug after completing the previous Phase I/II study (CA180031/NCT00337454)
Timeline
- Start
- 2006-01
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 50 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 70 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 90 mg | Oral |